Under LG Chem’s Wing, AVEO Oncology Steps On R&D Gas Pedal

Ficlatuzumab Combo Enters Phase III

With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.

business synergy
AVEO and LG Chem Reach First R&D Milestone After Integration • Source: Shutterstock

More from South Korea

More from Focus On Asia